Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction

NCT02698215 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT02698215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02698215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction
Lead sponsor
University of California, Los Angeles
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2016
Completion date
December 31, 2019
Enrollment
165 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder, nicotine dependence